Advertisement

Drugs

, Volume 72, Issue 9, pp 1243–1255 | Cite as

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed)

In Older Adults
  • Mark Sanford
Adis Drug Profile

Abstract

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [PCV13] is approved for protection against pneumococcal disease in children aged 6 weeks to 5 years and adults aged ≥50 years.

In randomized trials in adults aged 60–64 years (not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [PPV23]) and ≥70 years (previously vaccinated with PPV23), PCV13 was non-inferior to PPV23 in opsonophagocytic assay (OPA) geometric mean titres (GMTs) for all 12 serotypes common to the two vaccines. More PCV13 than PPV23 recipients had ≥4-fold increases in serotype 6A OPA GMTs (serotype 6A is not included in PPV23). PCV13 recipients also had higher OPA GMTs and met superiority criteria for most serotypes.

Adults aged 50–59 years had antibody responses to PCV13 that were noninferior to those in adults aged 60–64 years for all included serotypes. PCV13 administered concomitantly with trivalent inactivated influenza vaccine in adults aged 50–59 or ≥65 years produced antibody responses that were noninferior to those following sequential administration, except for influenza strain A/H3N2 and pneumococcal serotype 19F in those aged ≥65 years. Antibody responses were numerically higher with sequential administration, although the clinical significance of this is unknown.

Adverse events within 14 days of vaccination were mostly of mild-to-moderate severity, with serious events occurring in 0.2–1.4% of PCV13 and 0.4–1.7% of PPV23 recipients.

Keywords

Invasive Pneumococcal Disease Pneumococcal Disease Pneumococcal Pneumonia Sequential Administration Pneumococcal Serotypes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Lynch JP III, Zhanel GC. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010 May; 16 (3): 217–25PubMedGoogle Scholar
  2. 2.
    European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe 2009 [online]. Available from URL: http://www.ecdc.europa.eu/en/Publications/0910_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf [Accessed 2011 Nov 17]
  3. 3.
    van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009 Oct 31; 374 (9700): 1543–56CrossRefPubMedGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention. 2011. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, provisional, 2010 [online]. Available from URL: http://www.cdc.gov/abcs/reports-findings/survreports/spneu10.pdf. [Accessed 2012 Mar 14]
  5. 5.
    Metersky ML, Dransfield MT, Jackson LA. Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine?. Chest 2010 Sep; 138 (3): 486–90CrossRefPubMedGoogle Scholar
  6. 6.
    Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008 Nov 15; 47: 1328–38CrossRefPubMedGoogle Scholar
  7. 7.
    Conaty S, Watson L, Dinnes J, et al. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004; 22 (23–24): 3214–24CrossRefPubMedGoogle Scholar
  8. 8.
    Moberly SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008 Jan 23; (1): CD000422Google Scholar
  9. 9.
    Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009 Jan 6; 180 (1): 48–58CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomized and placebo-controlled trial. Lancet 2000 Jun 17; 355: 2106–11CrossRefPubMedGoogle Scholar
  11. 11.
    Herva E, Luotenen J, Timonen M, et al. The effect of polyvalent pneumococcal polysaccharide vaccine on nasophar-yngeal and nasal carriage of streptococcus pneumoniae. Scand J Inf Dis 1980; 12 (2): 97–100CrossRefGoogle Scholar
  12. 12.
    Goldblatt D. Conjugate vaccines. Clin Exp Immunol 2000 Jan; 119 (1): 1–3CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [Prevenar 13®]. Drugs 2010; 70 (15): 1973–86CrossRefPubMedGoogle Scholar
  14. 14.
    French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal vaccine in HIV-infected adults. N Engl J Med 2010 Mar 4; 362 (9): 812–22CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012 Mar; 31 (3): 297–301CrossRefPubMedGoogle Scholar
  16. 16.
    Dagan R, Patterson S, Juergens C, et al. Efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13; PCV7) in preventing nasopharyngeal colonization with PCV7 serotypes: a randomized, double-blind trial [abstract]. 8th International Symposium on Pneumococci and Pneumococcal Diseases; 2012 Mar 11–15; Iguacu FallsGoogle Scholar
  17. 17.
    Pfizer. Prevenar® 13: US prescribing information [online]. Available from URL: http://labeling.pfizer.com/ShowLabeling.aspx?id=501 [Accessed 2012 Apr 3]
  18. 18.
    European Medicines Agency. Prevenar 13: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf [Accessed 2012 Mar 3]
  19. 19.
    Pfizer. Pfizer receives FDA approval to extend use of Prevnar 13 for prevention of pneumococcal pneumonia and invasive disease in adults 50 years and older [online]. Available from URL: http://www.pfizer.com/news/ [Accessed 2012 Jan 24]
  20. 20.
    Jackson L, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [abstract no. O 425]. 21st European Congress of Clinical Microbiology and Infectious Diseases; 2011 May 7–10; MilanGoogle Scholar
  21. 21.
    Schwarz TF, Flamaing J, Rümke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 2011; 29 (32): 5195–202CrossRefPubMedGoogle Scholar
  22. 22.
    Greenberg RN, Gurtmann A, Frenck R, et al. A phase 3, randomized, active-controlled trial to evaluate the safety, tolerability, and immunogenicity of sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) administered at 1-year intervals in PPSV23-naive adults 60–64 years of age [abstract no. 665 plus poster). 49th Annual Meeting of the Infectious Diseases Society of America; 2011 Oct 20–23; Boston (MA)Google Scholar
  23. 23.
    Jackson L, Gurtman A, van Cleef K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in pneumococcal vaccine naive adults, 50–64 years of age [abstract no. O 426]. 21st European Congress of Clinical Microbiology and Infectious Diseases; 2011 May 7–10; MilanGoogle Scholar
  24. 24.
    Merck and Co., Inc. Pneumovax® 23 (pneumococcal vaccine polyvalent): US precribing information [online]. Available from URL: http://merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf [Accessed 2012 Mar 19]
  25. 25.
    US Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines [online]. Available from URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf [Accessed 2012 Mar 19]
  26. 26.
    Rozenbaum MH, Hak E, van der Werf TS, et al. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands. Clin Ther 2010; 32 (8): 1517–32CrossRefPubMedGoogle Scholar
  27. 27.
    Hak E, Grobbee DE, Sanders EAM, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66 (9): 378–83PubMedGoogle Scholar
  28. 28.
    Study evaluating a 13-valent pneumococcal conjugate vaccine (13vPnC) in adults (CAPITA) [ClinicalTrials.gov identifier NCT00744263]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 23]

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations